Please assess the completion status of the following clinical trial:

Trial Title: This is a Single Ascending Dose Tolerance Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria~* BMI 18.0 to 28.0 kg/m2,~* systolic blood pressure 90-140 mmHg,~* diastolic blood pressure 50-90 mmHg,~* heart rate 50 100 beats/min (all inclusive),~* clinically normal safety ECG and laboratory results~Exclusion Criteria~* relevant disease,~* treated with SLV354 before

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A1 (Type: EXPERIMENTAL): Part A, Parallel design Arm 1
- A2 (Type: EXPERIMENTAL): Part A, Parallel design Arm 2
- A3 (Type: EXPERIMENTAL): Part A, Parallel design Arm 3
- A4 (Type: EXPERIMENTAL): Part A, Parallel design Arm 4
- A5 (Type: EXPERIMENTAL): Part A, Parallel design Arm 5
- A6 (Type: EXPERIMENTAL): Part A, Parallel design Arm 6
- A7 (Type: EXPERIMENTAL): Part A, Parallel design Arm 7
- A8 (Type: EXPERIMENTAL): Part A, Parallel design Arm 8
- A9 (Type: PLACEBO_COMPARATOR): Part A, Parallel design Arm 9
- B1-1 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 1
- B1-2 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 2
- B2-1 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 3
- B2-2 (Type: EXPERIMENTAL): Part B, Cross-over design, Arm 4
- B3 (Type: PLACEBO_COMPARATOR): Part B, Cross-over design, Arm 5

Based on this trial design, predict the completion outcome and termination type (if applicable).